Publications & Presentations Our innovative development programs are backed by sound scientific research. Filter by All Publications Data Presentations Preliminary Patient Demographics and Baseline Characteristics From a Phase 3 Study (sunRIZE) of Ersodetug for Hypoglycemia Due to Congenital Hyperinsulinism: Trial in Progress Gopal Saha MBBS et al. ENDO 07/10/25 Global, multi-center, repeat-dose, phase 2 study of RZ358 (ersodetug), an insulin receptor antibody, for congenital hyperinsulinism Huseyin Demirbilek et al. Science Direct 06/13/25 RZ358 (Ersodetug) as a Novel Therapy for Hypoglycemia due to Tumor Hyperinsulinism: Outcomes from an Expanded Access Program for Compassionate Use Jonathan Strosberg MD et al. NANETS 12/05/24 The birth prevalence of congenital hyperinsulinism: a narrative review of the epidemiology of a rare disease David Lapidus et al. S. Karger AG 06/17/24 Topline Results: RZ402-201 Phase 2 Study in Patients with Diabetic Macular Edema (DME) Rezolute Webcast 05/21/24 An Analysis of Overnight Hypoglycemia in Patients with Congenital Hyperinsulinism: Results from the RZ358-606 (RIZE) Study Paul Thornton MD et al. Pediatric Endocrine Society (PES) 2024 NEJM Letter to the Editor: Anti–Insulin Receptor Antibody for Malignant Insulinoma and Refractory Hypoglycemia Soravis Osataphan MD et al. The New England Journal of Medicine 08/23/23 Treatment Of Severe Refractory Hypoglycemia Due To Malignant Insulinoma With A Novel Anti-Insulin Receptor Antibody Soravis Osataphan MD et al. ENDO 2023 Results from a Global, Multi-Center, Phase 2b Study (RIZE) in Congenital Hyperinsulinism: Characterization of a High Unmet Treatment Need and Glycemic Response to RZ358 Hüseyin Demirbilek ESPE 2022 A Single and Repeat-Dose Study of RZ358 in Patients with Post-Gastric Bypass Hypoglycemia (PGBH): Results of Population PK/PD Modeling Yongjun Hu PhD et al. ENDO 03/20/21 12
